Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

44066

Sigma-Aldrich

D-Sphingosine

≥98.0% (TLC)

Sinónimos:

Sphingosine, (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol, 4-Sphingenine, trans-D-erythro-2-Amino-4-octadecene-1,3-diol

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H37NO2
Número de CAS:
123-78-4
Peso molecular:
299.49
Beilstein/REAXYS Number:
1727294
EC Number:
204-651-3
MDL number:
MFCD00036751
UNSPSC Code:
12352211
PubChem Substance ID:
329756448
NACRES:
NA.85

assay

≥98.0% (TLC)

form

powder

lipid type

sphingolipids

storage temp.

−20°C

SMILES string

OC[C@@](N)([H])[C@]([H])(O)/C=C/CCCCCCCCCCCCC

InChI

1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1

InChI key

WWUZIQQURGPMPG-KRWOKUGFSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Biochem/physiol Actions

A constituent of cell membranes. Precursor of ceramide. Selective inhibitor of protein kinase C, but does not inhibit protein kinase A or myosin light chain kinase. Inhibitor of calmodulin-dependent enzymes.

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

hcodes

H413

Hazard Classifications

Aquatic Chronic 4

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 4

1 of 4

Ceramide (Brain) Ceramide (Brain, Porcine), powder

Avanti

860052P

Ceramide (Brain)

Sphingosine (d17:1) Avanti Research™ - A Croda Brand LM2000, ethanol solution

Avanti

LM2000

Sphingosine (d17:1)

Sphingosine kinase 1 Active human recombinant, expressed in baculovirus, ≥80% (SDS-PAGE)

Sigma-Aldrich

SRP0283

Sphingosine kinase 1 Active human

Sphingosine (d17:1) Avanti Research™ - A Croda Brand 860640P, powder

Avanti

860640P

Sphingosine (d17:1)

Meret E Ricklin et al.
Neurology, 81(2), 174-181 (2013-05-24)
To study the immune response against varicella-zoster virus (VZV) in patients with multiple sclerosis before and during fingolimod therapy. The VZV-specific immune response was studied using interferon (IFN)-γ enzyme-linked immunosorbent spot assay, proliferation assays, and upregulation of T-cell activation markers
Tim Ting Chiu et al.
The Journal of biological chemistry, 288(24), 17520-17531 (2013-05-04)
Insulin activates a cascade of signaling molecules, including Rac-1, Akt, and AS160, to promote the net gain of glucose transporter 4 (GLUT4) at the plasma membrane of muscle cells. Interestingly, constitutively active Rac-1 expression results in a hormone-independent increase in
David Henault et al.
Neurology, 81(20), 1768-1772 (2013-10-18)
To determine the range of fluctuation in total lymphocyte counts (TLCs) in peripheral blood over a 4- to 7-year period in patients with MS receiving fingolimod (FTY720) and the relation between TLCs and T-cell subsets (CD4+, CD8+, CCR7+/-) that are
Vilija G Jokubaitis et al.
Neurology, 82(14), 1204-1211 (2014-03-13)
To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to determine predictors of time to first relapse
Paolo Neviani et al.
The Journal of clinical investigation, 123(10), 4144-4157 (2013-09-04)
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However, CML quiescent HSCs are TKI resistant and represent a BCR-ABL1 kinase-independent disease reservoir. Here we
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico